Table 2 Diagnostic value of the anti-TAA autoantibodies panel of OC patients in different cohorts.
From: Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer
Cohort | Positive (%) | Se (%) | Sp (%) | YI | Accuracy (%) | PPV (%) | NPV (%) |  + LR | − LR | |
|---|---|---|---|---|---|---|---|---|---|---|
BC | NC | |||||||||
Training set (Validation cohort) | 75 (64.20) | 25 (21.43) | 58.59 | 80.47 | 0.39 | 69.53 | 75.00 | 66.02 | 3.00 | 0.51 |
Validation set (Discovery cohort) | 41 (58.57) | 15 (21.43) | 51.43 | 84.29 | 0.36 | 67.86 | 76.60 | 63.44 | 3.27 | 0.58 |
BD validation cohort (OC vs.BD) | 52 (64.20) | 32 (39.51) | 39.51 | 83.95 | 0.23 | 61.73 | 71.11 | 58.12 | 2.46 | 0.72 |
BD validation cohort (OC vs.BD + NC) | 52 (64.20) | 40 (49.38) | 51.85 | 80.86 | 0.33 | 71.19 | 57.53 | 77.06 | 2.71 | 0.60 |
